View printer-friendly version
« Back
June 16, 2004 5:08 p.m.
Teva Announces Approval Of Adenosine Injection

Jerusalem, Israel, June 16, 2004 - Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA) announced today that the U.S. Food and Drug Administration has granted
final approval for the Company's ANDA for Adenosine Injection USP, 3 mg/mL,which was submitted by the Company's subsidiary SICOR Inc. Shipment of this product, which has been approved in 2 mL and 4 mL vials, is expected to begin
immediately.

Teva's Adenosine Injection USP is the generic equivalent of Fujisawa's Adenocard® Injection. This product is indicated for conversion to sinus rhythm of paroxysmal supraventricular tachycardia (PSVT), including that associated with accessory bypass tracts (Wolff-Parkinson-White Syndrome).

The brand product has annual sales of approximately $13 million.

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 25
pharmaceutical companies and among the largest generic pharmaceutical companies
in the world. The company develops, manufactures and markets generic and
innovative human pharmaceuticals and active pharmaceutical ingredients. Close to
90% of Teva's sales are in North America and Europe.


Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on current expectations and involve a number of known and unknown risks and uncertainties that could cause Teva's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include Teva's ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competitive generic products, the impact of competition from brand-name companies that sell their own generic products or successfully extend the exclusivity period of their branded products, Teva's ability to rapidly integrate the operations of acquired businesses, including its recent acquisition of Sicor Inc., the availability of product liability coverage in the current insurance market, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration and other regulatory authority approvals, the regulatory environment and changes in the health policies and structure of various countries, acceptance and demand for new pharmaceutical products and new therapies, uncertainties regarding market acceptance of innovative products newly launched, currently being sold or in development, the impact of restructuring of clients, reliance on strategic alliances, exposure to product liability claims, dependence on patent and other protections for innovative products, fluctuations in currency, exchange and interest rates, operating results and other factors that are discussed in Teva's Annual Report on Form 20-F and its other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.